CRYSTAL Study: A Multi-Center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries.
Status: Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Mar 2019
Price : $35 *
At a glance
- Drugs Sirolimus (Primary) ; Everolimus
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms CRYSTAL
- Sponsors Micell Technologies
- 07 Mar 2019 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.
- 07 Mar 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.
- 07 Mar 2019 Planned initiation date changed from 31 Mar 2019 to 31 Dec 2019.